BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38086166)

  • 41. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer.
    Alektiar KM; McKee A; Venkatraman E; McKee B; Zelefsky MJ; Mychalczak BR; Hoskins WJ; Barakat RR
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):707-13. PubMed ID: 12062616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort.
    Wong AT; Rineer J; Schwartz D; Weiner J; Safdieh J; Choi K; Schreiber D
    Gynecol Oncol; 2017 Jan; 144(1):113-118. PubMed ID: 27823769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database.
    Nieto K; Adams W; Pham N; Block AM; Grover S; Small W; Harkenrider MM
    Gynecol Oncol; 2018 Jan; 148(1):147-153. PubMed ID: 29129389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study.
    Forsse D; Barbero ML; Werner HMJ; Woie K; Nordskar N; Berge Nilsen E; Ellstrøm Engh M; Vistad I; Rege A; Sævik-Lode M; Andreasen S; Haldorsen IS; Trovik J; Krakstad C
    Am J Obstet Gynecol; 2022 Jan; 226(1):90.e1-90.e20. PubMed ID: 34400137
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer.
    Hathout L; Wang Y; Wang Q; Vergalasova I; Elshaikh MA; Dimitrova I; Damast S; Li JY; Fields EC; Beriwal S; Keller A; Kidd EA; Usoz M; Jolly S; Jaworski E; Leung EW; Donovan E; Taunk NK; Chino J; Natesan D; Russo AL; Lea JS; Albuquerque KV; Lee LJ
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1423-1431. PubMed ID: 33677053
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
    Klopp AH; Jhingran A; Ramondetta L; Lu K; Gershenson DM; Eifel PJ
    Gynecol Oncol; 2009 Oct; 115(1):6-11. PubMed ID: 19632709
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study.
    Fakiris AJ; Moore DH; Reddy SR; Look KY; Yiannoutsos CT; Randall ME; Cardenes HR;
    Gynecol Oncol; 2005 Mar; 96(3):818-23. PubMed ID: 15721431
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-grade endometrial carcinoma limited to the endometrium or a polyp: is adjuvant treatment necessary?
    Dallaire Nantel L; Renaud MC; Gregoire J; Sebastianelli A; Plante M
    Int J Gynecol Cancer; 2021 Oct; 31(10):1335-1340. PubMed ID: 34518241
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Uterine papillary serous and clear cell carcinomas: Comparison of characteristics and clinical outcomes.
    Yuce Sari S; Guler OC; Oymak E; Gultekin M; Yigit E; Kahvecioglu A; Yuce K; Celik H; Usubutun A; Bolat F; Onal C; Yildiz F
    J Obstet Gynaecol Res; 2022 Jul; 48(7):1876-1887. PubMed ID: 35385171
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer.
    Townamchai K; Berkowitz R; Bhagwat M; Damato AL; Friesen S; Lee LJ; Matulonis U; O'Farrell D; Viswanathan AN
    Gynecol Oncol; 2013 Apr; 129(1):18-21. PubMed ID: 23262378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
    Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
    Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
    Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
    J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is there a survival advantage in diagnosing endometrial cancer in asymptomatic postmenopausal patients? An Israeli Gynecology Oncology Group study.
    Gemer O; Segev Y; Helpman L; Hag-Yahia N; Eitan R; Raban O; Vaknin Z; Leytes S; Ben Arie A; Amit A; Levy T; Namazov A; Volodarsky M; Ben Shachar I; Atlas I; Bruchim I; Lavie O
    Am J Obstet Gynecol; 2018 Aug; 219(2):181.e1-181.e6. PubMed ID: 29792852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of care in women with high-intermediate risk endometrioid adenocarcinoma in the PORTEC-2 era: A SEER database analysis.
    Zavitsanos PJ; Leonard KL
    Brachytherapy; 2017; 16(1):109-115. PubMed ID: 27780688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
    Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer.
    Solhjem MC; Petersen IA; Haddock MG
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1379-84. PubMed ID: 16029796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation.
    Martinez AA; Weiner S; Podratz K; Armin AR; Stromberg JS; Stanhope R; Sherman A; Schray M; Brabbins DA
    Gynecol Oncol; 2003 Sep; 90(3):537-46. PubMed ID: 13678721
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma.
    Mundt AJ; Murphy KT; Rotmensch J; Waggoner SE; Yamada SD; Connell PP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1154-60. PubMed ID: 11483324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. External beam management of stage I and II uterine cancer.
    Edwards DM; Jolly S
    Int J Gynecol Cancer; 2022 Mar; 32(3):297-303. PubMed ID: 35256415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.